SEC Form SC 13D/A filed by T2 Biosystems Inc. (Amendment)

SEC Form SC 13D/A filed by T2 Biosystems Inc. (Amendment)

Recent Analyst Ratings for $TTOO

$TTOO Financials

$TTOO Leadership Updates

$TTOO SEC Filings

$TTOO Press Releases

$TTOO Analyst Ratings

$TTOO Large Ownership Changes

$TTOO Insider Trading

$TTOO Market Insights

Recent Analyst Ratings for
$TTOO

$TTOO
Financials

$TTOO
Leadership Updates

$TTOO
SEC Filings

$TTOO
Press Releases

$TTOO
Analyst Ratings

$TTOO
Large Ownership Changes

$TTOO
Insider Trading

$TTOO
Market Insights

Chat with this insight

Live finance-specific insights

T2 Biosystems to Host Business Update Call on October 10, 2024

T2 Biosystems Announces Second Quarter 2024 Financial Results

T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024

Live Leadership Updates

Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer

T2 Biosystems Appoints Laura Adams to Its Board of Directors

T2 Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

T2 Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

T2 Biosystems Inc. filed SEC Form 8-K: Regulation FD Disclosure

Fastest customizable press release news feed in the world

T2 Biosystems to Host Business Update Call on October 10, 2024

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

T2 Biosystems upgraded by Alliance Global Partners with a new price target

Alliance Global Partners resumed coverage on T2 Biosystems with a new price target

T2 Biosystems downgraded by Alliance Global Partners with a new price target

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by T2 Biosystems Inc.

Amendment: SEC Form SC 13G/A filed by T2 Biosystems Inc.

SEC Form SC 13D/A filed by T2 Biosystems Inc. (Amendment)

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Elsbree David B sold $133 worth of shares (55 units at $2.42), decreasing direct ownership by 71% to 23 units (SEC Form 4)

Cr Group L.P. converted options into 1,824,800 shares (SEC Form 4)

Cr Group L.P. was granted 4,748,335 shares (SEC Form 4)

Live Market Insights

T2 Biosystems Announces Commercial Expansion Through Hong Kong And Macau Distributor; T2 Biosystems Will Sell The T2dD Instrument, The T2Bacteria Panel, The T2Candida Panel, And The T2Resistance Panel Through The Newly Appointed Distributor

T2 Biosystems Regains Compliance With Nasdaq

12 Health Care Stocks Moving In Thursday's Intraday Session

5/7/24 7:46:58 PM ET

$TTOO

Medical/Dental Instruments

Health Care

Get the next $TTOO alert in real time by email

SC 13D/A 1 d79053dsc13da.htm SC 13D/A SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

T2 Biosystems, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

89853L302

(CUSIP Number)

Andrei Dorenbaum

c/o CR Group L.P.

1000 Main Street, Suite 2500

Houston, TX 77002

(703) 209-7350

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 3, 2024

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).


CUSIP No. 89853L302				Page 2 of 11


1.		Names of Reporting Persons Nathan D. Hukill
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☒ (1) (b) ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO (2)
5.		Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 8,853,173
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 8,853,173

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

(2)	The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

(3)	This percentage is calculated based on 13,541,285 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer.


CUSIP No. 89853L302				Page 3 of 11


1.		Names of Reporting Persons CR Group L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☒ (1) (b) ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO (2)
5.		Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 8,853,173
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 8,853,173

(1)

Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D..

(2)	The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

(3)	This percentage is calculated based on 13,541,285 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer.


CUSIP No. 89853L302				Page 4 of 11


1.		Names of Reporting Persons CRG Partners III L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☒ (1) (b) ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO (2)
5.		Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,330,175
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,330,175

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

(2)	The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

(3)	This percentage is calculated based on 13,541,285 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer.


CUSIP No. 89853L302				Page 5 of 11


1.		Names of Reporting Persons CRG Partners III – Parallel Fund“A” L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☒ (1) (b) ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO (2)
5.		Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 828,324
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 828,324

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

(2)	The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

(3)	This percentage is calculated based on 13,541,285 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer.


CUSIP No. 89853L302				Page 6 of 11


1.		Names of Reporting Persons CRG Partners III (Cayman) Unlev AIV I L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☒ (1) (b) ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO (2)
5.		Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 266,038
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 266,038

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

(2)	The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

(3)	This percentage is calculated based on 13,541,285 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer.


CUSIP No. 89853L302				Page 7 of 11


1.		Names of Reporting Persons CRG Partners III (Cayman) Lev AIV I L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☒ (1) (b) ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO (2)
5.		Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 3,548,707
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 3,548,707

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

(2)	The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

(3)	This percentage is calculated based on 13,541,285 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer.


CUSIP No. 89853L302				Page 8 of 11


1.		Names of Reporting Persons CRG Partners III Parallel Fund “B” (Cayman) L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☒ (1) (b) ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions) OO (2)
5.		Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 2,879,929
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 2,879,929

(1)	Nathan D. Hukill, CR Group L.P., CRG Partners III L.P., CRG Partners III – Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P., and CRG Partners III Parallel Fund “B” (Cayman) L.P. are members of a group for the purposes of this Schedule 13D.

(2)	The shares of the Common Stock of the Issuer were acquired in exchange for and satisfaction of such partial debt cancellation of certain loans outstanding held by the group.

(3)	This percentage is calculated based on 13,541,285 shares of Common Stock issued and outstanding as of May 3, 2024, as provided by the Issuer.

Explanatory Note

This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D supplements and amends the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on April 19, 2024 (together, as so amended, the “Schedule 13D”) jointly by each of the following persons (collectively, the “Reporting Persons”): Nathan D. Hukill (“Mr. Hukill”), a citizen of the United States, CR Group L.P., a Delaware limited partnership (“CR Group”), CRG Partners III – Parallel Fund “A” L.P., a Delaware limited partnership (“CRG Parallel Fund A”), CRG Partners III (Cayman) Unlev AIV I L.P., a Cayman Islands exempted limited partnership (“CRG Unlev AIV”), CRG Partners III (Cayman) Lev AIV I L.P., a Cayman Islands exempted limited partnership (“CRG Lev AIV”), and CRG Partners III Parallel Fund “B” (Cayman) L.P., a Cayman Islands exempted limited partnership (“CRG Parallel Fund B” and collectively with CRG Parallel Fund A, CRG Unlev AIV and CRG Lev AIV, the “CRG Funds”). Except as otherwise specified in this Amendment No. 1, all items in the Schedule 13D remain unchanged. All capitalized terms used herein and not otherwise defined have the meanings ascribed to such terms in the Schedule 13D.

The Reporting Persons are filing this Amendment No. 1 to report certain changes in their beneficial ownership of the common stock, par value $0.001 per share (the “Common Stock”), of T2 Biosystems, Inc., a Delaware corporation (the “Issuer”) as result of certain transactions in Common Stock of the Issuer.

Item 3. Source and Amount of Funds or Other Consideration

The response to Item 3 in the Schedule 13D is hereby amended and restated as follows:

The information set forth in Items 5 and 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 3.

All of the shares reported on this Schedule 13D were acquired from the Issuer in exchange for the Reporting Persons’ cancellation of outstanding loans to the Issuer under that certain Term Loan Agreement, dated as of December 30, 2016, as amended, by and among the Issuer and CRG Servicing LLC, as administrative agent and collateral agent, and the lenders named therein. The most recent acquisitions occurred on April 12, 2024 and May 3, 2024. Refer to the Issuer’s current reports on Form 8-K filed on July 6, 2023, February 15, 2024, April 18, 2024 and May 6, 2024 for additional information.

Item 5. Interest in Securities of the Issuer

The response to Item 5 in the Schedule 13D is hereby amended and restated as follows:

The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2 and 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

By virtue of the relationships among the Reporting Persons described herein, the Reporting Persons may be deemed to constitute a group within the meaning of Section 13(d)(5) of the rules and regulations promulgated by the Securities and Exchange Commission pursuant to the Exchange Act. As such, pursuant to Rule 13d-3 under the Exchange Act, such group may be deemed to beneficially own an aggregate of 8,853,173 shares of Common Stock, representing in the aggregate approximately 65.4% of the issued and outstanding shares of Common Stock, as calculated pursuant to Rule 13d-3 under the Exchange Act.

Except as set forth in this Schedule 13D, none of the Reporting Persons has effected any transactions in Common Stock during the last 60 days.

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.


CUSIP No. 89853L302				Page 10 of 11

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby amended and restated in its entirety to read:

The information set forth in Items 3 and 4 of this Schedule 13D is incorporated by reference in its entirety to this Item 6.

Item 7. Material to be Filed as Exhibits

Joint Filing Agreement*

*	Previously filed.


CUSIP No. 89853L302				Page 11 of 11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 7, 2024


Nathan D. Hukill

/s/ Nathan D. Hukill
An individual

CR Group L.P. CRG Partners III L.P. CRG Partners III – Parallel Fund“A” L.P. CRG Partners III (Cayman) Unlev AIV I L.P. CRG Partners III (Cayman) Lev AIV I L.P. CRG Partners III Parallel Fund “B” (Cayman) L.P.

By:		/s/ Nathan D. Hukill
		Nathan D. Hukill, authorized signatory

Get the next $TTOO alert in real time by email

Aggregate Amount Beneficially Owned by Each Reporting Person

8,853,173

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

☐

Percent of Class Represented by Amount in Row (11)

65.4% (3)

Type of Reporting Person (See Instructions)

IN